NFKB1 and Alzheimer disease: The additional interactions of miR-29 in cancer should also be investigated in AD; for example, NF-κB, which is known to be up-regulated in AD, was shown to target miR-29 in cholangiocarcinoma, but to date has not been shown to target this miRNA in AD (Lukiw et al., 2008).